top of page

Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

SAB Biotherapeutics, Inc. - Common Stock (NQ:SABS)

4.485 +0.035 (+0.79%)

Streaming Delayed Price Updated: 9:30 AM EST, Feb 4, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about SAB Biotherapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 Next >

SAB Biotherapeutics to Present at the BIO CEO & Investor Conference

February 23, 2024

From SAB Biotherapeutics, Inc.

Via GlobeNewswire

SAB Biotherapeutics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference

February 08, 2024

From SAB Biotherapeutics, Inc.

Via GlobeNewswire

SAB Biotherapeutics Announces Executive Leadership Change

February 02, 2024

From SAB Biotherapeutics, Inc.

Via GlobeNewswire

Analyst Ratings for SAB Biotherapeutics ↗

August 21, 2023

Via Benzinga

SAB Biotherapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement

January 23, 2024

From SAB Biotherapeutics, Inc.

Via GlobeNewswire

Why Applied Therapeutics Shares Are Trading Lower By Over 35%? Here Are Other Stocks Moving In Friday's Mid-Day Session ↗

January 05, 2024

Shares of Applied Therapeutics, Inc.

Via Benzinga

Cal-Maine Foods, UniFirst And 3 Stocks To Watch Heading Into Wednesday ↗

January 03, 2024

With U.S. stock futures trading lower this morning on Wednesday, some of the stocks that may grab investor focus today are as follows:

Via Benzinga

SAB Biotherapeutics Announces 1-for-10 Reverse Stock Split

January 02, 2024

From SAB Biotherapeutics, Inc.

Via GlobeNewswire

VerifyMe And 3 Other Stocks Under $2 Insiders Are Buying ↗

December 01, 2023

The Dow Jones closed higher by more than 500 points on Thursday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders...

Via Benzinga

Topics Stocks

SAB Biotherapeutics Announces Commencement of the HUMAN Phase 1 Clinical Trial with SAB-142, a Potential Disease-Modifying Treatment for Type 1 Diabetes

November 29, 2023

From SAB Biotherapeutics, Inc.

Via GlobeNewswire

EXCLUSIVE: SAB Biotherapeutics Kickstarts Phase 1 Study For Its Lead Type 1 Diabetes Hopeful In Australia ↗

November 29, 2023

SAB Biotherapeutics Inc (NASDAQ: SABS) announced that the first HUMAN trial participants (Fully HUman anti-thymocyte biologic in a first-in-MAN clinical study) have been dosed in Australia.

Via Benzinga

SAB Biotherapeutics Appoints Katie Ellias to the Board of Directors

November 20, 2023

From SAB Biotherapeutics, Inc.

Via GlobeNewswire

12 Health Care Stocks Moving In Thursday's Intraday Session ↗

November 16, 2023

Via Benzinga

SAB Biotherapeutics Announces Completion of $67.1 Million Financing to Advance Potential Disease-Modifying Treatment for Type 1 Diabetes

November 14, 2023

From SAB Biotherapeutics, Inc.

Via GlobeNewswire

SAB Biotherapeutics Announces Q3 2023 Financial Results and Provides Company Updates

November 14, 2023

From SAB Biotherapeutics, Inc.

Via GlobeNewswire

SAB Biotherapeutics to Present at Piper Sandler Healthcare Conference

November 09, 2023

From SAB Biotherapeutics, Inc.

Via GlobeNewswire

12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗

October 24, 2023

Via Benzinga

SAB Biotherapeutics Appoints Michael G. King Jr. as Chief Financial Officer

October 24, 2023

Finance leader joins SAB with more than 25 years of experience as a leading biotech equity research analyst

From SAB Biotherapeutics, Inc.

Via GlobeNewswire

Nasdaq Falls 100 Points; AT&T Posts Upbeat Earnings ↗

October 19, 2023

U.S. stocks traded lower toward the end of trading, with the Nasdaq Composite falling around 100 points on Thursday. The Dow traded down 0.43% to 33,520.17 while the NASDAQ fell 0.75% to 13,214.04. The...

Via Benzinga

Topics Stocks

12 Health Care Stocks Moving In Thursday's Intraday Session ↗

October 19, 2023

Via Benzinga

Why Nokia Shares Are Trading Lower By Over 5%? Here Are Other Stocks Moving In Thursday's Mid-Day Session ↗

October 19, 2023

Gainers

Via Benzinga

12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗

October 19, 2023

Via Benzinga

SAB Biotherapeutics Receives Australian Approval to Commence Phase 1 Clinical Trial of SAB-142, a Potential Disease-Modifying Treatment for Type 1 Diabetes

October 19, 2023

From SAB Biotherapeutics, Inc.

Via GlobeNewswire

Benzinga's Top Ratings Upgrades, Downgrades For October 5, 2023 ↗

October 05, 2023

Via Benzinga

SAB Biotherapeutics Approves Appointment of Andrew Moin to Board of Directors

October 05, 2023

SAB also announces closing of $7.5 million financing, the first tranche of $130 million private placement

From SAB Biotherapeutics, Inc.

Via GlobeNewswire

12 Health Care Stocks Moving In Monday's Pre-Market Session ↗

October 02, 2023

Via Benzinga

SAB Biotherapeutics Announces Private Placement of up to $130 Million to Advance Development of Lead Drug Candidate for Type 1 Diabetes

October 02, 2023

From SAB Biotherapeutics, Inc.

Via GlobeNewswire

EXLUSIVE: SAB Biotherapeutics To Raise Up To $130M Via Preferred Equity To Advance Development Of Lead Diabetes Candidate ↗

October 02, 2023

SAB Biotherapeutics (NASDAQ: SABS) has entered into a securities purchase agreement with certain investors to issue and sell shares of preferred stock in a private placement of up to $130 million in...

Via Benzinga

Why SeaStar Medical Holding Shares Are Trading Higher By Around 35%? Here Are Other Stocks Moving In Friday's Mid-Day Session ↗

September 29, 2023

Gainers Blue Apron Holdings, Inc. (NASDAQ: APRN) climbed 133.5% to $12.82 after the company announced an agreement to be acquired by Wonder Group for $13 per share.

Via Benzinga

12 Health Care Stocks Moving In Monday's Intraday Session ↗

August 28, 2023

Via Benzinga

< Previous 1 2 3 4 5 6 7 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

220 S. Main St.
Colville, WA 99114

Hours: Mon.-Fri., 8 a.m.-5 p.m.

509-684-4567
editor@statesmanexaminer.com

Site by Amber S. King – Creative Design

Home
About
Contact
Submissions

bottom of page